In 1978, Stibler and co-workers' observed an increase in serum transferrin fractions with an isoelectric point (pl) of 25.7 in the cerebrospinal fluid and serum of alcoholic patients and proposed the use of these transferrin fractions as markers for excessive alcohol consumption. Since then, numerous studies have been carried out to assess their clinical performance2 l5 and several reviews have been published.'6-18
In 1978, Stibler and co-workers' observed an increase in serum transferrin fractions with an isoelectric point (pl) of 25.7 in the cerebrospinal fluid and serum of alcoholic patients and proposed the use of these transferrin fractions as markers for excessive alcohol consumption. Since then, numerous studies have been carried out to assess their clinical performance2 l5 and several reviews have been published.'6- 18 Human transferrin (molecular mass -80 000 Da) is the principal iron-transporting glycoprotein in plasma. It is synthesized and metabolized mainly in the liver. The molecule is a single polypeptide with two N-linked oligosaccharide side chainsI9 which are attached posttranslationally by a multi-glucosyltransferase system. The side chains exhibit considerable microheterogeneity in branching and content of terminal sialic acid. Differences in the number of terminal sialic acid groups give rise to isoforms of different PI. The major transferrin has four sialic acid residues (tetrasialotransferrin), two on each carbohydrate side chain? and a PI of 5.4. Minor isoforms with two or three sialic acid groups (di-and tri-sialotransferrin, respectively) and hence higher pl (5.7 and 5.6, respectively), and with five or six sialic acid (penta-and hexasialotransferrin, respectively) and hence lower PI values (5.3 and 5.2, respectively) are normally present in smaller amounts.*" The term 'carbohydrate deficient transferrin' (CDT) refers to the di-, mono-(PI of 5.8) and asialotransferrin (PI of 5.9) forms.2 Transferrin has two iron binding sites per molecule and is usually one-third saturated with ferric ions. The difference in both iron-saturation and the sialic acid content results in a difference in charge of the various isoforms. Methods for CDT measurement must be able to distinguish between transferrin deficient in sialic acid residues and normal transferrins that lack iron. When normal serum transferrin is iron-free This article was prepared under the auspices of the Analytical Investigations Standing Committee of the Scientific Committee of the Association of Clinical Biochemists.
Correspondence to: D r Y Foo the PI is 5.8. When fully saturated with iron, the PI is 5. 45 . Microheterogeneity of serum transferrin in relation to its iron content, which overlaps with variations in sialic acid content, can be overcome by iron-saturating the serum. During the last two decades, serum CDT has emerged as a marker of alcohol abuse but has not been widely used, partly because of the cumbersome nature of the methods involved, their poor performance and the lack of consensus about what should be measured. This personal view aims to highlight the deficiencies of current methods and suggest ways forward.
METHODS
Several methods have been developed for the analysis of CDT based on charge difference of the isoforms. Early methods were qualitative. The transferrin isoforms were separated by isoelectric focusing (IEF) and the fractions demonstrated by staining directly or after immunofixation. The results were interpreted visually and reported as isoform bands present or absent.'.21-2' Subsequently, the bands were quantitated by densitometric scanning and results expressed as a per cent or an index of total t r a n~f e r r i n .~~~~~~~~-"
In 1991, Xin et a1.28 improved on the detection method, using immunoblot (IB) following IEF on high resolution agarose gels. The focused proteins were transferred electrophoretically onto a nitrocellulose membrane and stained immunochemically with anti-human transferrin antibody. The method has served as the gold standard for the validation of most CDT procedures.
Most current CDT methods are charge-based separation procedures using anion exchange chromatography or IEF with detection by various immunoassays: radioimmunoassay (RIA), enzyme immunoassay (EIA), immunoblot and turbidimetry. High-performance liquid chromatography (HPLC) has also been developed for the measurement of CDT.
Fast protein liquid chromatography (FPLC; Pharmacia, Uppsala, Sweden)29 and HPLC'O may also be used to separate the transferrin isoforms, and after separation transferrin fractions can be quantitated directly by spectrophotometry or by RIA. In FPLC, transferrin isoforms are eluted by a continuous salt gradient. Di-, mono-and asialotransferrins are measured by RIA. The HPLC method using Mono Q column (Pharmacia) is fully automated with auto-injection. CDT eluted with a salt gradient is quantitated by absorbance measurement at 460nm. Results are expressed as a percentage of total transferrin.
COMMERCIALLY AVAILABLE METHODS
Anion exchange chromatography followed by RIA (CDTectTM, Pharmacia) has become the dominant commercially available method. In the original method,* serum samples are first saturated with ferric citrate followed by separation on mini disposable anion exchange columns. The chromatographic separation was based on pH using a low ionic strength piperazine buffer with critical pH of 5.65. Isoforms with ~1 2 5 . 7 were collected in the eluate and assayed in duplicate by RIA. However, the low ionic strength buffer was unstable and a new modified method was introduced in 19913' with a buffer of increased ionic strength and a pH of 5.7. Only isoforms with PI> 5.7 were measured with this modified method, hence lower CDT values were obtained. To avoid the use of radio-isotopes, the manufacturer has also developed an alternative competitive microtitre plate EIA for quantitating the CDT fraction (CDTectTM Enzyme Immunoassay).
Percentage CDT-RIA and YO CDT-TIA (turbidimetric immunoassay) are procedures manufactured by Axis Biochemicals (Oslo, Norway). In the former technique, '251-labelled antitransferrin antibody is mixed with iron-saturated serum and binds to transferrin in the sample. The complexes formed have different PI and most complexes are retained on the column. Complexes with low pI pass through the column and complexes with di-, mono-and asialotransferrins are eluted with buffer containing sodium chloride. The radioactivity in the eluate is measured by a y-counter. Percentage CDT is obtained from a standard curve constructed from serum with known YO CDT assigned by HPLC.
Percentage CDT-TIA separates CDT from normal transferrin in iron-saturated serum by anion exchange chromatography using a minicolumn. However, this method measures 50% of the tri-asialotransferrins, in addition to the di-, mono-and asialotransferrin isoforms. CDT eluted from the column and total transferrin present in the sample are measured by immunoturbidimetry using the same anti-human transferrin antibody. CDT and total transferrin levels are obtained from the same calibration curve constructed from human transferrin and % CDT value is calculated. The major advantage of this method is that the immunoturbidimetric step can be easily adapted to routinely available analysers, making it semi-automated.
Another recent similar semi-automated method is the % CDT by Boehringer Mannheim (Mannheim, Germany). The procedure also involves anion exchange chromatography followed by immunoturbidimetric measurement of the CDT in the eluate and total transferrin in the sample. The CDT and total transferrin levels are obtained from the same standard curve derived from human transferrin standardized according to CRM 470 and the result is expressed as % CDT of total transferrin. This method measures asialo-, mono-, di-and trisialo-transferrins.
The only IEF technique commercially available is the Specialty's IEF (Specialty Laboratories, Santo Monica, USA) with laser densitometry.'* CDTs are separated from normal transferrin isoforms by IEF. Identification of transferrin bands is carried out by incubation with anti-transferrin followed by a second antibody conjugated to alkaline phosphatase enzyme. Colour is developed by addition of the enzyme substrate. CDTs are quantitated as a ratio of total transferrin using laser densitometry. Table 1 summarizes the manufacturers providing commercial CDT reagent kits.
LINEARITY AND DETECTION LIMIT
Linearity and detection limit are generally acceptable as most procedures are linear up to at least eight to ten times the upper reference limit and detect acceptable lower levels.
PROBLEMS WITH CURRENT CDT METHODS

Standardization
HPLC methods do not require a standard since CDT is expressed as % of total transferrin. For IEF/IB, a CDT standard was prepared by separating iron-saturated human transferrin by anion exchange chromatography into four 
Imprecision
The Pharmacia CDTect is the only procedure for which the manufacturer recommends carry- Table 2 . Most of the procedures are imprecise, with interassay CVs ranging from 7.5 to 21%. This is unsatisfactory for monitoring alcoholics. Only two methods managed to achieve interassay CV of less than 7%.
Quality control
Although most commercial kits provide quality control material to be included in each run, there are currently no external quality assurance schemes for CDT measurement in the UK. There is, therefore, no independent measure of how widely laboratories diverge in the results reported.
Interference
Plasma cannot be used, as commonly used anticoagulants such as citrate, oxalate, EDTA and heparin interfere with anion exchange chromatography. Fasting serum should be used. Most of the commonly prescribed drugs do not interfere with the ion exchange chromatography separation step, nor does opiate therapy or abuse. Results from subjects with genetic variants and patients with carbohydrate deficient glycoprotein syndrome (CDGS) should be interpreted with caution. The D variant has a different amino acid sequence compared to the usual C allele, and gives falsely high CDT values by methods using anion exchange chromatography.'3 With IEF, D variant showed isoforms cathodal to the usual bands and isoforms above PI 5.9. 34 The separation pattern and retention times using HPLC also allows detection of the D ~a r i a n t . '~ CDGS is a newly recognized hereditary multi-systemic syndrome with an autosomal recessive inheritance. The most striking biochemical abnormality in these patients is the presence of secretory glycoproteins that are deficient in their carbohydrate moieties. In the CDT assay using anion exchange chromatography, these patients have levels approximately 10 times the upper reference limit. Increased values have also been reported in healthy heterozygotes. IEF and HPLC show prominent bands with pI of 5.7.3h-38
DISCUSSION
In order to make headway in sorting out the CDT assays some consensus agreement has to be reached regarding the following issues:
1 Which transferrin isoforms should be measured? Should these be limited to just di-, mono-and asialotransferrins or should trisialotransferrin be included? Heggli et al.3y have suggested that it should be included because the metabolic process converting high to low sialic acid transferrin is a continuous process and that tri-asialotransferrin was shown to be elevated in alcoholics. Variations occur between methods because different methods do not measure the same transferrin fractions, and there are disproportional alcohol-induced increases in the different fractions. Differences generally occur at the chromatographic step, which is dependent on several factors such as gel buffer, column size and iron saturation. Generally, the more diasialotransferrin that is eluted, the higher the CDT values. 2 How should the results be expressed? As %CDT of total transferrin or as absolute concentration in mg/L or U/L? Although absolute concentrations could be reported, it may be advisable to report as %CDT for the following reasons. There is a large variation of total transferrin concentrations in women (with increases due to iron deficiency and estrogen administration) and in highly intoxicated alcoholics who are likely to be malnourished. Decreases in total transferrin are seen in liver dysfunction and acute phase reactions. Several author^^,^^ 45 have shown better diagnostic performance using %CDT compared to absolute levels, although 48 reported no difference between the two ways of expressing results.
A universal calibrator is required to standardize the procedure and to improve the analytical performance. However, this problem can be overcome if a consensus is reached to report results as %CDT of total transferrin. Because no specific antibody against CDT has been produced to date, all current methods involve a separation step followed by quantitation of CDT fractions. Hence the imprecision of methods is unsatisfxtory varying from I to 21%.
CONCLUSION
In our opinion, the most suitable CDT method must measure disialotransferrin, in addition to mono-and asialotransferrin isoforms, since disialotransferrin is the principal fraction elevated in alcoholics. Whether tri-asialotransferrin should be included in the measurement remains controversial and requires a consensus. If it is to be included then it should be measured in total, and not just half as in the %CDT TIA kit of Axis. The clinical performance of such measurements will require further evaluation. In view of the clinical variation in total transferrin and the lack of a calibrator, it would undoubtedly be advantageous to express the result as %CDT of total transferrin. IEF and HPLC methods detect all the transferrin isoforms as well as genetic variants. IEF with IB is tedious and requires technical skill and expertise. The instrumentation is costly and the method is not suitable for large batches. Automated HPLC may be a possibility for laboratories with HPLC set-up.
The alternative is anion exchange chromatographic separation followed by automated immunoturbidimetric measurement on a routine analyser. This is cheaper and more applicable for most routine laboratories but the imprecision of the assays must be taken into consideration when monitoring changes in CDT in alcoholics. The ideal solution would be a specific antibody raised against CDT which would eliminate the initial separation step. This will undoubtedly improve the precision and reduce assay time.
